Adelaide, AUS, July 22, 2020 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been contracted to conduct a clinical
study of Atossa Therapeutics' proprietary drug candidate AT-301, to be administered by nasal spray. Avance has
successfully completed multiple clinical studies of Atossa's proprietary Endoxifen.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop
innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19.
Yvonne Lungerhausen, CEO, Avance Clinical said:
"Avance Clinical is very pleased to be working with Atossa Therapeutics again on their second COVID-19 Therapeutic
Development Program. Atossa is a valued long-term client that clearly understands the excellence in clinical research
available in Australia, and the many benefits of conducting studies in the region."
According to Atossa Therapeutics:
AT-301 is Atossa's proprietary formula intended for nasal administration in patients immediately following diagnosis of
COVID-19 but who have not yet exhibited symptoms severe enough to require hospitalization. It is intended for at-home
use to proactively reduce symptoms of COVID-19 and to slow the infection rate so that a person's immune system can more
effectively fight SARS-CoV-2 (coronavirus). Atossa also intends to conduct testing to determine whether AT-301 can be
used as a prophylaxis to prevent or mitigate SARS-CoV-2.
The study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult
subjects divided into two study groups. Part A consists of two single-dose cohorts receiving either active therapy,
AT-301B, or the placebo comparator AT-301A. Part B is a multiple dose arm with cohorts receiving either AT-301A or
AT-301B for 14 days. The primary objective of the study is to evaluate the safety and tolerability of single and
multiple doses of AT-301 administered via nasal instillation to healthy volunteers. Secondary objectives are to assess
the incidence and severity of local irritation and bronchospasm following administration of AT-301 via nasal
instillation.
"Our AT-301 nasal spray program is being developed for COVID-19 patients who are not hospitalized, which complements our
AT-H201 program being developed for COVID-19 patients on ventilators," commented Steven Quay, M.D., Ph.D., President and
CEO of Atossa. "Many COVID-19 patients are infected via the nasal passage, which makes a nasal spray therapy potentially
very attractive. Collectively, the components of AT-301 are believed to replicate a 'vaccine-like mechanism' to help
maintain a protective mucosal barrier within the nasal cavity with anti-viral properties that may lead to lower
infectivity and reduced symptoms in COVID-19 patients due to their interference with the spike protein of the virus in
the nasal cavity and upper respiratory tract. We may eventually develop AT-301 as a prophylaxis to reduce risk of being
infected with COVID-19. For example, it could be taken as a daily vaccine-like treatment for people at higher-risk, such
as TSA workers, emergency medical professionals and hospital personnel," concluded Dr. Quay.
An application to commence the study has been submitted to the relevant institutional review board (IRB) and local
regulatory authority in Australia which must be approved before commencement of the study. Pending these approvals,
Atossa expects that the study will commence this quarter. Adequate and well-controlled studies to demonstrate safety and
efficacy must be successfully completed and regulatory approvals must be obtained before AT-301 may be commercialized.
Atossa has filed provisional patent applications on AT-301 to treat patients diagnosed with, or to prevent, COVID-19 via
nasal spray.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative
medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. For more
information, please visit www.atossatherapeutics.com.
See full announcement here https://tinyurl.com/y46rcp33About Avance Clinical
Australia's Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research
Organizations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the
pursuit of drug development for a healthier world.
Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team. The
collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of
experts who also demonstrate passion in their chosen field.
Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class
Investigators and Sites able to access specialized patient groups. Visit http://www.avancecro.com for more information.
Other benefits include:
1. The Government R grant means up to 43.5% rebate on clinical trial spend
2. Telehealth pivot during COVID-19 pandemic - speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5-6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA
compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of
Australia's counter-flu and allergy seasons